Intelligent people have no obstacle in their growth
Nandini Roy Choudhury, writer
Brief news
- Jakob Uszkoreit co-founded biotech startup Inceptive after working as a researcher at Google.
- Uszkoreit recommended the use of self-attention for training neural networks, which later evolved into the transformer architecture.
- Inceptive, with a focus on integrating AI into medication development, secured $100 million in funding and aims to design RNA using generative AI for more harmonious drug interactions with biological systems.
Detailed news
Before he co-founded the biotech startup Inceptive, Jakob Uszkoreit had a concept that would eventually enable the development of generative artificial intelligence. In 2017, Uszkoreit was employed as a researcher at Google, with the objective of expediting the training of neural networks.
He recommended employing a novel method of data interpretation known as self-attention. That notion was replaced by the transformer, the neural network architecture that serves as the foundation of generative AI.
“There are applications, such as those at Google and other locations, where transformers have been deployed in production for a long time, but there has been significantly less fanfare,” Uszkoreit stated in a June interview with CNBC. He stated that the applications were “reflected in the spotlight” by OpenAI’s ChatGPT, which was introduced in late 2022.
Uszkoreit and seven other Google researchers published the transformer concept in the 2017 paper “Attention Is All You Need.” Since that time, each of the eight authors has departed from Google.
“It is possible that Google has not been as daring as a much smaller company like OpenAI in its application of this technology to a variety of products,” Uszkoreit stated. “This is something that we must accept and, in a sense, even be grateful for, as Google is providing a service to the world that we all rely on on a daily basis.”
In 2021, Uszkoreit departed Google to co-found Inceptive, which he characterises as a biological software company. In an effort to integrate artificial intelligence into medication development, Inceptive secured $100 million in a funding round that was spearheaded by Andreessen Horowitz and Nvidia in September.
Uszkoreit stated, “We are commencing with a focus on RNA, whose precise composition has been designed using generative artificial intelligence. This design ensures that the molecules within specific biological systems exhibit behaviours that are ultimately native to those systems.” “There is actually this promise of a drug flavour that is in much greater harmony with living systems than the majority of current medications.”
Source : CNBC News
